Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AmpliMed Corporation
Tucson, Arizona, United Statesamplimed.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
AmpliMed's lead compound Amplimexon showed promising results in Phase I/II trials for metastatic melanoma. When combined with dacarbazine, patients with less advanced disease had a survival advantage of 11.7 months compared to approximately 8 months for dacarbazine-treated historical controls. The drug demonstrated relatively infrequent side effects even when administered with full-dose chemotherapy.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
Beyond the preview
Go deeper on AmpliMed Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AmpliMed Corporation.